In a comparative clinical study in patients with operable HER2-positive breast cancer receiving neoadjuvant chemotherapy, PF-05280014 demonstrated non-inferior PK and similar efficacy, safety and immunogenicity to trastuzumab-EU [14]. This evidence concerns the gene ERBB2 and breast cancer.